@article {MANOUCHEHRI6593, author = {JASMINE M. MANOUCHEHRI and MICHAEL KALAFATIS}, title = {Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment}, volume = {37}, number = {12}, pages = {6593--6599}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Triple-negative breast cancer (TNBC) is the most fatal form of breast cancer due to the shortcomings of therapies. However, recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is a promising anticancer therapeutic that possesses the capability to promote the induction of apoptosis in cancer cells, but some TNBCs are resistant to rhTRAIL{\textquoteright}s pro-apoptotic effects. Therefore, a combinatorial treatment approach with silibinin and rhTRAIL was considered in order to sensitize rhTRAIL-resistant TNBCs. Materials and Methods: The co-treatment of rhTRAIL and silibinin{\textquoteright}s impact on apoptosis induction in rhTRAIL-resistant TNBC BT-20 and HCC1937 cells was inspected via application of Annexin V/PI assays and western blot analysis. Results: Silibinin possessed the ability to sensitize the examined rhTRAIL-resistant TNBC cells to rhTRAIL-induced apoptosis through the up-regulation of death receptors 4 and 5 and the down-regulation of survivin transcriptionally. Conclusion: Silibinin is a good sensitizing agent for rhTRAIL-resistant TNBCs.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/12/6593}, eprint = {https://ar.iiarjournals.org/content/37/12/6593.full.pdf}, journal = {Anticancer Research} }